[PMID: 9102927] PubMed record related to this compound for laboratory literature review
50 , e330e335 (2021)
Head-to-head trials should compare long-term benefits of different combination regimens
GHK-Cu: Copper tripeptide evaluated for up-regulation of growth factors (e.g., TGF-related pathways), collagen production, and antioxidant activity
This study is a global, randomized, double-blind, placebo-controlled clinical trial (n=11000) aimed at evaluating the effectiveness and safety of Zilebesiran (300mg, subcutaneous injection, once every 6 months) combined with standard treatment (OC) compared to placebo combined with SOC in reducing the incidence of major cardiovascular adverse events (MACE) in hypertensive adult patients with diagnosed cardiovascular disease or poor blood pressure control at high risk of cardiovascular disease
Complete Transparency No hidden charges or surprise bills End-to-End Insurance Handling Complete insurance processing support Up to 20% Savings on Every Surgery powered by smarter insurance handling Easy EMI Options Flexible payment plans available 120CrPatient Savings Delivered so patients focus on recovery, not bills